Back

Immune Cell Densities Predict Response to Immune Checkpoint-Blockade in Head and Neck Cancer

Ruiz Torres, D. A.; Bryan, M. E.; Hirayama, S.; Merkin, R. D.; Evelyn, L.; Roberts, T.; Patel, M.; Park, J. C.; Wirth, L. J.; Sadow, P. M.; Sade-Feldman, M.; Stott, S. L.; Faden, D. L.

2024-09-12 oncology
10.1101/2024.09.10.24313432 medRxiv
Show abstract

Immune checkpoint blockade (ICB) is the standard of care for recurrent/metastatic head and neck squamous cell carcinoma (HNSCC), yet efficacy remains low. The current approach for predicting the likelihood of response to ICB is a single proportional biomarker (PD-L1) expressed in immune and tumor cells (Combined Positive Score, CPS) without differentiation by cell type, potentially explaining its limited predictive value. Tertiary Lymphoid Structures (TLS) have shown a stronger association with ICB response than PD-L1. However, their exact composition, size, and spatial biology in HNSCC remain understudied. A detailed understanding of TLS is required for future use as a clinically applicable predictive biomarker. MethodsPre-ICB tumor tissue sections were obtained from 9 responders (complete response, partial response, or stable disease) and 11 non-responders (progressive disease) classified via RECISTv1.1. A custom multi-immunofluorescence (mIF) staining assay was designed, optimized, and applied to characterize tumor cells (pan-cytokeratin), T cells (CD4, CD8), B cells (CD19, CD20), myeloid cells (CD16, CD56, CD163), dendritic cells (LAMP3), fibroblasts ( Smooth Muscle Actin), proliferative status (Ki67) and immunoregulatory molecules (PD1). Spatial metrics were compared among groups. Serial tissue sections were scored for TLS in both H&E and mIF slides. A machine learning model was employed to measure the effect of these metrics on achieving a response to ICB (SD, PR, or CR). ResultsA higher density of B lymphocytes (CD20+) was found in responders compared to non-responders to ICB (p=0.022). A positive correlation was observed between mIF and pathologist identification of TLS (R2= 0.66, p-value= <0.0001). TLS trended toward being more prevalent in responders to ICB (p=0.0906). The presence of TLS within 100 {micro}m of the tumor was associated with improved overall (p=0.04) and progression-free survival (p=0.03). A multivariate machine learning model identified TLS density as a leading predictor of response to ICB with 80% accuracy. ConclusionImmune cell densities and TLS spatial location within the tumor microenvironment play a critical role in the immune response to HNSCC and may potentially outperform CPS as a predictor of ICB response.

Matching journals

The top 4 journals account for 50% of the predicted probability mass.

1
OncoImmunology
24 papers in training set
Top 0.1%
21.7%
2
Clinical Cancer Research
64 papers in training set
Top 0.1%
11.8%
3
Journal for ImmunoTherapy of Cancer
75 papers in training set
Top 0.2%
10.9%
4
Frontiers in Immunology
638 papers in training set
Top 2%
6.2%
50% of probability mass above
5
Frontiers in Oncology
103 papers in training set
Top 0.6%
5.4%
6
Cancers
213 papers in training set
Top 1%
5.4%
7
npj Precision Oncology
53 papers in training set
Top 0.4%
3.2%
8
eLife
5828 papers in training set
Top 49%
1.7%
9
Cell Reports Medicine
153 papers in training set
Top 2%
1.7%
10
Journal of Clinical Investigation
179 papers in training set
Top 3%
1.7%
11
Cancer Research Communications
51 papers in training set
Top 0.9%
1.7%
12
Journal of Translational Medicine
57 papers in training set
Top 0.8%
1.7%
13
British Journal of Cancer
49 papers in training set
Top 0.9%
1.5%
14
Nature Communications
5641 papers in training set
Top 51%
1.1%
15
European Journal of Cancer
11 papers in training set
Top 0.3%
1.0%
16
Cancer Cell
42 papers in training set
Top 1%
1.0%
17
Journal of Experimental & Clinical Cancer Research
25 papers in training set
Top 0.6%
1.0%
18
Molecular Oncology
55 papers in training set
Top 1%
1.0%
19
eBioMedicine
183 papers in training set
Top 5%
0.9%
20
Translational Oncology
21 papers in training set
Top 0.8%
0.8%
21
Modern Pathology
22 papers in training set
Top 0.4%
0.8%
22
JNCI: Journal of the National Cancer Institute
19 papers in training set
Top 0.4%
0.8%
23
Cancer Immunology, Immunotherapy
12 papers in training set
Top 0.4%
0.6%
24
Breast Cancer Research
36 papers in training set
Top 0.7%
0.6%
25
Scientific Reports
3612 papers in training set
Top 79%
0.6%
26
Cancer Immunology Research
35 papers in training set
Top 1.0%
0.6%
27
Neuropathology and Applied Neurobiology
15 papers in training set
Top 0.5%
0.6%
28
JCO Precision Oncology
14 papers in training set
Top 0.4%
0.6%